Bloomberg

Departing Pharma CEOs Leave Warning Sales for Successors to Solve

Departing Pharma CEOs Leave Warning Sales for Successors to Solve

  • września 01, 2016
  • min read

Bloomberg

Departing Pharma CEOs Leave Warning Sales for Successors to Solve

Investor unrest has brought transition to the top at numerous pharmaceutical companies. In most cases, CEOs are passing the baton after a very successful run, said Michael Kunst, a Munich-based partner with Bain & Company. Their successors will have to navigate increasingly thorny discussions about price and regulation, which is why many companies choose executives from within who already know the business, Kunst said.

"There's a lot mounting up in terms of challenges in an industry that's seen smoother sailing," Kunst said. "These companies are getting into rougher waters, but none are a complete turnaround case that needs new and fresh thinking from outside. The first port of call is definitely internal."